<DOC>
	<DOCNO>NCT02489331</DOCNO>
	<brief_summary>Post marketing surveillance safety efficacy Cholib Korean patient `` New Drug Re-examination ''</brief_summary>
	<brief_title>Post Marketing Surveillance Safety Efficacy Cholib Korean Patients Under `` New Drug Re-examination '' .</brief_title>
	<detailed_description>The objective surveillance identify problem question Cholib® follow matter condition investigational product use . 1 . Serious adverse event adverse drug reaction profile - Death life-threatening condition - Hospitalization prolong hospitalization - Persistent significant disability/incapacity - Congenital anomaly/birth defect - Other medically significant event 2 . Unexpected adverse event/adverse drug reaction profile 3 . Known adverse drug reaction profile 4 . Non-serious adverse drug reaction profile 5 . Other information relate product safety 6 . Efficacy evaluation 7 . Study extend follow-up Surveillance safety efficacy subject receive Cholib® long-term use least 24 week . 8 . Study special patient Analysis specific patient elderly patient ( 65 year ) , patient renal/hepatic disease</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Clinical diagnosis mixed dyslipidaemia high triglyceride low HDL cholesterol level LDL cholesterol level adequately control correspond dose simvastatin monotherapy Patients hypersensitive ( allergic ) peanut , soybean ingredient medicine Patients experience photoallergy phototoxic reaction treatment fibrates ketoprofen Patients active hepatic disorder serum transaminase increase continuously without identify reason Patients gallbladder disease Patients chronic acute pancreatitis except acute pancreatitis due severe hypertriglyceridemia Patients moderately severely reduced kidney function ( estimate glomerular filtration rate &lt; 60mL/min/1.73m2 ) Cholib® administration combine administration fibrates , statin , danazol , cyclosporine strong cytochrome P450 ( CYP ) 3A4 inhibitor 145/40mg Cholib® Combined administration amiodarone , verapamil , amlodipine diltiazem Children &lt; 19 year Pregnant breastfeeding woman Patients biliary cirrhosis Patients myopathy and/or previously rhabdomyolysis myopathy take statin and/or fibrates 5 time creatine phosphokinase Upper limit Normal ( ULN ) take statin previously Patients rare hereditary problem lactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption since drug contains lactose Patients rare hereditary problem fructose intolerance , glucosegalactose malabsorption sucraseisomaltase deficiency since drug contains sucrose Patients LDL Cholesterol ≥130 mg/dL triglyceride &lt; 150mg/dL HDL cholesterol ≥60mg/dL Investigators refer product market authorization ( label ) inclusion/exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Dyslipidemias</keyword>
</DOC>